Knowledge Distillery

Filter the news according their assigned tags.
| Interventional study with open label/non-randomised methodology  

Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial

COVID-19 is associated with a prothrombotic state leading to adverse clinical outcomes. Whether therapeutic anticoagulation improves outcomes in…

more...

Therapeutics

| Interventional study with open label/non-randomised methodology  

Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India

ZyCoV-D is a DNA vaccine candidate, which comprises a plasmid DNA carrying spike-S gene of SARS-CoV-2 virus along with gene coding for signal peptide.…

more...

Vaccination

| Interventional study with open label/non-randomised methodology  

Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial

The antibacterial, anti-inflammatory, and antiviral properties of azithromycin suggest therapeutic potential against COVID-19.

more...

Therapeutics

| Interventional study with open label/non-randomised methodology  

Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Azithromycin, an antibiotic with potential antiviral and anti-inflammatory properties, has been used to treat COVID-19, but evidence from community…

more...

Therapeutics

| Interventional study with open label/non-randomised methodology  

Interleukin-6 receptor antagonists in critically ill patients with covid-19

The efficacy of interleukin-6 receptor antagonists in critically ill patients with COVID-19 is unclear. In this article the authors evaluated…

more...

Therapeutics